Perbak Capital Partners LLP Purchases 14,512 Shares of Vaxcyte, Inc. $PCVX

Perbak Capital Partners LLP boosted its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 54.9% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 40,931 shares of the company’s stock after purchasing an additional 14,512 shares during the quarter. Vaxcyte accounts for about 0.3% of Perbak Capital Partners LLP’s holdings, making the stock its 29th largest holding. Perbak Capital Partners LLP’s holdings in Vaxcyte were worth $1,474,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of PCVX. Norges Bank purchased a new position in shares of Vaxcyte during the 2nd quarter valued at $32,109,000. Westfield Capital Management Co. LP raised its position in shares of Vaxcyte by 42.4% in the second quarter. Westfield Capital Management Co. LP now owns 3,068,898 shares of the company’s stock worth $99,770,000 after buying an additional 913,761 shares in the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of Vaxcyte in the second quarter worth $26,318,000. State Street Corp boosted its stake in Vaxcyte by 12.1% during the second quarter. State Street Corp now owns 4,942,235 shares of the company’s stock valued at $160,672,000 after buying an additional 534,552 shares during the period. Finally, Eventide Asset Management LLC boosted its stake in Vaxcyte by 80.4% during the second quarter. Eventide Asset Management LLC now owns 848,141 shares of the company’s stock valued at $27,573,000 after buying an additional 377,911 shares during the period. 96.78% of the stock is owned by institutional investors.

Analyst Ratings Changes

PCVX has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, January 9th. Jefferies Financial Group reiterated a “buy” rating on shares of Vaxcyte in a research report on Tuesday. Guggenheim reissued a “buy” rating and set a $116.00 price objective on shares of Vaxcyte in a report on Monday, February 2nd. Leerink Partners set a $77.00 price objective on shares of Vaxcyte and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Finally, BTIG Research raised their target price on shares of Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Vaxcyte currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.50.

Vaxcyte Stock Performance

NASDAQ:PCVX opened at $54.58 on Friday. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $76.61. The firm has a market cap of $7.86 billion, a PE ratio of -9.71 and a beta of 1.31. The business has a 50 day moving average price of $54.08 and a 200-day moving average price of $45.80.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, February 24th. The company reported ($1.80) EPS for the quarter, missing the consensus estimate of ($1.46) by ($0.34). During the same period in the prior year, the firm earned ($1.12) EPS. Research analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Insiders Place Their Bets

In other news, COO Jim Wassil sold 7,395 shares of the stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $58.88, for a total transaction of $435,417.60. Following the completion of the sale, the chief operating officer directly owned 166,818 shares in the company, valued at approximately $9,822,243.84. This represents a 4.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Elvia Cowan sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $58.59, for a total value of $146,475.00. Following the completion of the sale, the chief accounting officer directly owned 30,867 shares in the company, valued at $1,808,497.53. The trade was a 7.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 31,261 shares of company stock valued at $1,593,767 in the last quarter. Insiders own 3.10% of the company’s stock.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.